Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
82705-0010-01 82705-0010 Epcoritamab-bysp EPKINLY 48.0 mg/.8mL Immunotherapy Monoclonal Antibody CD20, CD3 Subcutaneous May 19, 2023 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug. 5, 2020 June 30, 2024 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2018 July 31, 2021 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct. 31, 2017 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 July 31, 2025 In Use
00703-5075-01 00703-5075 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Aug. 27, 1998 May 31, 2024 In Use
00703-5075-03 00703-5075 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Aug. 27, 1998 Feb. 29, 2024 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct. 24, 2018 Sept. 30, 2024 In Use
00574-0866-10 00574-0866 Cyclosporine Cyclosporine 50.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Intravenous Oct. 7, 2003 Aug. 1, 2024 In Use
00574-0930-10 00574-0930 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 25, 2021 April 30, 2024 In Use
00574-0931-25 00574-0931 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 25, 2021 April 30, 2024 In Use
00591-5019-02 00591-5019 Fulvestrant Fulvestrant 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 22, 2019 June 30, 2024 In Use
00781-3474-32 00781-3474 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Intravenous May 26, 2021 In Use
00955-1727-20 00955-1727 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 7, 2014 Jan. 31, 2025 In Use
16714-0248-01 16714-0248 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 28, 2023 In Use
50242-0210-12 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 28, 2022 In Use
50242-0210-60 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-83 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-86 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 15, 2020 Feb. 11, 2022 In Use
50242-0210-90 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
16729-0223-61 16729-0223 temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug. 13, 2018 In Use
23155-0170-31 23155-0170 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Aug. 31, 2023 In Use
23155-0649-41 23155-0649 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Intravenous Oct. 1, 2019 In Use
23155-0687-41 23155-0687 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0688-41 23155-0688 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0689-41 23155-0689 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0790-41 23155-0790 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Intravenous March 1, 2021 In Use
42388-0011-14 42388-0011 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
42388-0012-14 42388-0012 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
50742-0496-26 50742-0496 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 1, 2023 In Use
50742-0497-53 50742-0497 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 1, 2023 In Use
50742-0498-05 50742-0498 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 1, 2023 In Use
50742-0521-10 50742-0521 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 19, 2021 In Use
51991-0890-33 51991-0890 Erlotinib Hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 April 30, 2024 In Use
51991-0891-33 51991-0891 Erlotinib Hydrochloride Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
51991-0892-33 51991-0892 Erlotinib Hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
51991-0942-98 51991-0942 Dexrazoxane Hydrochloride Dexrazoxane 500.0 mg/50mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous June 26, 2017 Aug. 31, 2024 In Use
54838-0555-50 54838-0555 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 27, 2011 Nov. 30, 2024 In Use
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00121-0885-08 00121-0885 Prednisolone Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 12, 2023 In Use
00121-0885-16 00121-0885 Prednisolone Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 12, 2023 In Use
00143-9292-01 00143-9292 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Sept. 29, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-13 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-61 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00480-4053-56 00480-4053 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 21, 2023 In Use
00480-4320-01 00480-4320 Plerixafor Plerixafor 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous July 28, 2023 In Use

Found 10,000 results in 8 milliseconds — Export these results